NewcelX Ltd. has appointed Dr. Camillo Ricordi, a globally recognized expert in diabetes cure research and islet transplantation, to its Scientific Advisory Board. This move follows NewcelX's successful FDA Pre-IND meeting for its lead stem-cell therapy NCEL-101, which aims to restore insulin production in Type 1 diabetes patients. Dr. Ricordi's expertise will support NewcelX's clinical development and strategic collaboration with Eledon Pharmaceuticals, advancing potential transformative treatments for Type 1 diabetes. The appointment strengthens NewcelX's leadership as it prepares for clinical trials and further development of its regenerative medicine platform.
Sandler, part of Trilliad, introduced the Sales Performance Ecosystem, the first platform to evaluate sales skills during actual buyer conversations using AI-powered coaching. This system links training directly to revenue by measuring real behavior ...
Pacira BioSciences awarded inducement grants to 10 new employees, including stock options for 9,200 shares and restricted stock units for 18,200 shares, as part of its Amended 2014 Inducement Plan. These awards, approved by the company's compensation...
Medallion Financial Corp., a specialty finance company, will announce its financial results for the quarter ending June 30, 2026, after market close on July 29, 2026. A conference call to discuss these results is scheduled for July 30 at 9:00 a.m. ET...
Quest Software has obtained FedRAMP High authorization for its Quest Identity Defense and Quest Identity Recovery products on Microsoft Azure Government, making it the only provider with a FedRAMP High SaaS offering for hybrid Active Directory and Mi...
Healthier Choices Management Corp. (HCMC) has acquired 420,000 Eyes on Monitor ($EOM) tokens, about 1% of the total supply, through its AI-driven platform RAGE. This move follows a prior investment in $DONT DisclaimerCoin tokens and reflects HCMC's s...
